Pharmaceuticals

Orally Disintegrating Tablet Market Growth Projection: Expected to Surpass $24.43 Billion by 2030 at 8.5% CAGR

February 17, 2026February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the orally disintegrating tablet market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Orally Disintegrating Tablet Market be in 2030 compared with 2026?

The orally disintegrating tablet market size has shown strong growth in recent years. It is forecast to increase from $16.2 billion in 2025 to $17.62 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.8%. Historically, the expansion observed in this market can be linked to aspects like limited awareness of orally disintegrating tablets, the dominance of conventional tablets, minimal targeting of pediatric and geriatric demographics, reliance on hospital pharmacy channels, and the slow adoption of specialty drug formulations.

The orally disintegrating tablet market is projected to experience substantial expansion over the coming years. This market is set to reach $24.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. Factors contributing to this growth during the forecast period include innovations in ODT formulation technology, a growing patient preference for ease of use and adherence, the expansion of online and retail pharmacy channels, an increase in the occurrence of CNS and gastrointestinal disorders, and enhanced research and development in anti-psychotics and anti-epileptics. Key trends anticipated in this period encompass a growing demand for dosage forms that are simple to swallow and patient-centric, an increase in targeting pediatric and geriatric patient populations, the enlargement of hospital and retail pharmacy distribution networks, a heightened emphasis on fast-acting therapeutics, and the increasing incorporation of specialty drug categories within ODT formulations.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp

What Drivers Are Guiding Growth Patterns In The Orally Disintegrating Tablet Market?

The increasing prevalence of neurological disorders is anticipated to drive the expansion of the orally disintegrating tablet market moving forward. Neurological disorders are health conditions that impact the nervous system, encompassing the brain and peripheral nerves, and interfere with its normal functioning. The growing number of neurological disorders is primarily attributed to people living longer, as age-related conditions such as Alzheimer’s and Parkinson’s become more common, resulting in an overall surge in cases. Orally disintegrating tablets assist in managing neurological disorders by enabling easier and faster medication administration, particularly beneficial for patients with dysphagia (difficulty swallowing) or cognitive impairments, thereby improving treatment adherence, ensuring punctual dosing, and enhancing the overall effectiveness of therapy. For example, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, stated that in 2023, roughly 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia, with projections suggesting this figure will rise to 13.8 million by 2060. Hence, the rising incidence of neurological disorders is fueling the growth of the orally disintegrating tablet market.

Which Segments Are Driving Activity In The Orally Disintegrating Tablet Market?

The orally disintegrating tablet market covered in this report is segmented –

1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes

2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores

4) By Consumer Type: Pediatric, Adult, Geriatric

Subsegments:

1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics

2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics

3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants

4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics

5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs

6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives

7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs

8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids

9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole

10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes

Which Trends Are Shaping Activity Within The Orally Disintegrating Tablet Market?

Major companies in the orally disintegrating tablet market are concentrating on innovations in drug formulation, such as patient-centric drug delivery systems, to improve treatment adherence and patient outcomes. A patient-centric drug delivery system refers to designing and providing medicines in a way that makes them easier and more comfortable for patients to take, enhancing their treatment experience and compliance. For instance, in May 2025, Viatris Inc., a US-based healthcare company, launched Gen-Clozapine orally disintegrating tablets (ODT) in Canada, offering a new treatment option for treatment-resistant schizophrenia. This product features several unique aspects, making it a significant enhancement for managing treatment-resistant schizophrenia in Canada. As the first clozapine orally disintegrating tablet (ODT) available in the country, it provides a patient-friendly alternative that rapidly disintegrates in the mouth without water, assisting those with swallowing difficulties or adherence issues. The product is offered in multiple strengths (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), allowing for flexible and precise dose titration based on individual patient needs. By incorporating clozapine, the only approved antipsychotic for treatment-resistant schizophrenia, the ODT formulation aligns with established treatment protocols.

Which Major Industry Participants Are Leading The Orally Disintegrating Tablet Market Growth?

Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Orally Disintegrating Tablet Market?

North America was the largest region in the orally disintegrating tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Orally Disintegrating Tablet Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25857&type=smp

Browse Through More Reports Similar to the Global Orally Disintegrating Tablet Market 2026, By The Business Research Company

Tablets Market Report 2026

https://www.thebusinessresearchcompany.com/report/tablets-global-market-report

Effervescent Tablet Market Report 2026

https://www.thebusinessresearchcompany.com/report/effervescent-tablet-global-market-report

Oral Solid Dosage Pharmaceutical Formulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-pharmaceutical-formulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795